Who Paid My Doc
Anthony Prousi
Dentist, Oral and Maxillofacial Surgery Burlington, NJ Medical Doctor
NPI 1992934830 CMS profile 961105
1900 Mount Holly Road, Bldg 500, Burlington, NJ 08016
General payments
$12,235
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Anthony Prousi of Burlington, NJ is reported in the CMS Open Payments database as having received $12,235 across 100 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 96th percentile of Dentist, Oral and Maxillofacial Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $31 | 2 | |
| 2024 | General | $227 | 24 | |
| 2023 | General | $208 | 17 | |
| 2022 | General | $11,421 | 22 | |
| 2020 | General | $119 | 11 | |
| 2019 | General | $229 | 24 |
Beside peers
- Anthony Prousi
- Dentist, Oral and Maxillofacial Surgery median
- Middle half of Dentist, Oral and Maxillofacial Surgery
- National median
In program year 2025, general payments to Anthony Prousi were reported at $31. Among 3,834 Dentist, Oral and Maxillofacial Surgery profiles paid that year, the median was $150 and the middle half received between $56 and $423.
Show as a table
| Year | Anthony Prousi | Dentist, Oral and Maxillofacial Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $229 | $142 | $50–$420 | $163 |
| 2020 | $119 | $96 | $36–$277 | $114 |
| 2021 | $0 | $138 | $45–$419 | $132 |
| 2022 | $11,421 | $144 | $48–$367 | $149 |
| 2023 | $208 | $153 | $55–$399 | $160 |
| 2024 | $227 | $152 | $50–$400 | $164 |
| 2025 | $31 | $150 | $56–$423 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
316
Drug cost
$909
Branded share of claims
15.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Amoxicillin | Generic | 119 | $307 | |
| Chlorhexidine Gluconate | Generic | 76 | $296 | |
| Clindamycin Hcl | Generic | 15 | $108 | |
| Azithromycin | Generic | 28 | $95 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 49 | $85 | |
| Tramadol Hcl | Generic | 29 | $19 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,440 Part D prescribers listed as Oral Surgery (Dentist only); they describe a distribution and say nothing about conduct.
Records
100 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Dentist, Oral and Maxillofacial Surgery in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Dentist, Oral and Maxillofacial Surgery
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.